A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

被引：0
|
作者：
Segal, Neil Howard
Hodi, F. Stephen
Sanborn, Rachel E.
Gajewski, Thomas
Wolchok, Jedd D.
Urba, Walter John
Fox, Bernard A.
Topallan, Suzanne Louise
Pardoll, Drew M.
Kollia, Georgia
McDonald, Dan
Kim, Su Young
Sharfman, William Howard
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Earle A Chiles Res Inst & Providence Canc Ctr, Portland, OR USA
[3] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3115
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors
    Sanbom, Rachel E.
    Sharfman, William Howard
    Segal, Neil Howard
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Urba, Walter John
    Fox, Bernard A.
    Topalian, Suzanne Louise
    Pardoll, Drew M.
    Covello, Kelly L.
    McDonald, Dan
    Kim, Su Young
    Gupta, Ashok Kumar
    Wigginton, Jon M.
    Gajewski, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [3] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [4] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
    Callahan, Margaret K.
    Bendell, Johanna C.
    Chan, Emily
    Morse, Michael
    Pillai, Rathi Narayana
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    Chau, Ian
    Calvo, Emillano
    Le, Dung T.
    Ott, Patrick Alexander
    Taylor, Matthew Hiram
    Sharma, Padmanoo
    Antonia, Scott Joseph
    Sharkey, Brian
    Christensen, Olaf
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors
    Chow, Laura Quan Man
    Gordon, Michael S.
    Logan, Theodore F.
    Antonia, Scott J.
    Bhatia, Shailender
    Thompson, John A.
    Brahmer, Julie R.
    Solberg, Gretchen
    Bittner, Rachel
    Fontana, David
    Grosso, Joseph
    Cohen, Lewis J.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [7] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
    Topalian, Suzanne Louise
    Sznol, Mario
    Brahmer, Julie R.
    McDermott, David F.
    Smith, David C.
    Gettinger, Scott N.
    Taube, Janis M.
    Drake, Charles G.
    Pardoll, Drew M.
    Powderly, John D.
    Carvajal, Richard D.
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    Antonia, Scott J.
    Spigel, David R.
    Lawrence, Donald P.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Wigginton, Jon M.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
    Sangro, Bruno
    Crocenzi, Todd S.
    Welling, Theodore Hobart
    Inarrairaegui, Mercedes
    Prieto, Jesus
    Fuertes, Carmen
    Delanty, Laurie
    Feely, William
    Anderson, Jeffrey
    Grasela, Dennis M.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Hodi, F. S.
    Topalian, S. L.
    Brahmer, J. R.
    McDermott, D. F.
    Smith, D. C.
    Gettinger, S.
    Taube, J. M.
    Pardoll, D. M.
    Wigginton, J. M.
    Sznol, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [10] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345